


Agilent Discovery Services

TURBOCHARGE DISCOVERY THROUGHPUT
ASSAY DEVELOPMENT, HTS, AND ADME
USING RAPIDFIRE TECHNOLOGY

The Measure of Confidence



Agilent Technologies

RESOLVE BOTTLENECKS WITH UNPRECEDENTED TURNAROUND TIMES

In the highly competitive drug development world, pharmaceutical and biotechnology organizations require an outsourcing partner that can provide the highest quality data in increasingly shorter time periods. Agilent Discovery Services is at the forefront of contract research providers with RapidFire High-throughput Mass Spectrometry, which delivers thousands of data points in just a couple of days.

Take advantage of RapidFire technology

Agilent Discovery Services uses RapidFire technology because it performs truly label-free analysis of functional biochemical assays, making possible the direct measurement of native analytes and the side-by-side assessment of multiple reaction products. Sensitive, analytical results are delivered in just 6 to 8 seconds per sample, without the need for antibodies, luminescent substrates, or radioactive reagents and their associated costs.

Take the lead in pipeline development

As a result of faster turnaround times for assay development, lead compound identification, and ADME analysis, Agilent Discovery Services helps you gain a competitive edge. Your scientists are armed with fast, accurate, and sensitive results that give them flexibility to make important decisions about potential lead candidates much earlier in the drug discovery process. Overall, you can identify stronger drug candidates and improve your drug discovery pipeline.



Agilent Discovery Services provides efficient access to revolutionary RapidFire technology without an investment in instrument ownership and maintenance.

Laborious sample preparation is not required – simply send your quenched 96 or 384-well plates to Agilent Discovery Services.

Proven Assay Development For Even The Most Difficult Targets


Agilent's in-house, PhD-level scientists bring decades of mass spectrometry expertise to your project. We have successfully screened millions of test compounds for clients working in a wide range of therapeutic areas. With RapidFire high-throughput technology, it is also possible to detect compounds which have proven challenging, costly, or impossible to tackle using traditional approaches.

Lead discovery

RapidFire technology enables the direct quantitation of native products and substrates to provide robust, physiologically relevant data with fewer false positives. It yields an enriched data set for primary and secondary screening, SAR, and ADME applications on a single platform. In addition, RapidFire technology frees assay developers from the time consuming and difficult tasks of antibody (Ab) generation and validation. Targets that are challenging or impossible with traditional methods are now accessible, expanding your options.

In Vitro ADME

Agilent provides key information for critical *in vitro* ADME assays using the efficient RapidFire platform: CYP inhibition, time-dependent DDI, metabolic stability, permeability, and plasma protein binding. The Agilent Discovery Services *in vitro* ADME offering increases your laboratory's productivity while preserving your assay method integrity. Researchers continue with the same workflows, quench the assay plates, and simply send them to Agilent for analysis.



Learn more

www.agilent.com/lifesciences/discoveryservices

Contact us

1-781-928-2700

discoveryservices@agilent.com

For Research Use Only. Not for use in
diagnostic procedures. This information
is subject to change without notice.

© Agilent Technologies, Inc., 2012
Published in the USA, April 10, 2012
5991-0200EN



Agilent Technologies